GILD vs RGA
GILD: Gilead Sciences is a global biopharmaceutical leader specializing in transformative medicines for HIV, liver disease, and oncology. RGA: A leading global reinsurer specializing in life and health risk management and capital-efficient financial solutions for insurance carriers.
Side-by-side fundamentals
| Metric | GILD | RGA | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $170.68 | $264.73 | |
| Market cap | $211.7B | $17.3B | |
| P/E as of 2026-10-30 | n/a | 11.66 | |
| PEG as of 2026-10-30, 3-year EPS CAGR to FY2025 | n/a | 0.36 | |
| Net margin FY2025, SEC XBRL | +28.9% | +5.0% | GILD higher |
| Operating margin FY2025, SEC XBRL | +34.0% | n/a | |
| ROE FY2025, SEC XBRL | +37.6% | +8.8% | GILD higher |
| ROA FY2025, SEC XBRL | +14.4% | +0.8% | GILD higher |
| Debt / equity | 2.01 | 0.42 | RGA lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +2.4% | +7.2% | RGA higher |
| Revenue CAGR (3y) SEC XBRL | +2.6% | +13.5% | RGA higher |
| Dividend yield as of 2026-09-03 | 1.92% | 1.48% | GILD higher |
| Dividend streak (yrs) SEC XBRL | 11 | 18 | RGA higher |
| Beta as of 2026-09-03 | 0.34 | 0.74 | |
| 1-year return as of 2026-10-30 close | +44.1% | +40.1% | GILD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.